The 14-item short health anxiety inventory (SHAI-14) used as a screening tool: appropriate interpretation and diagnostic accuracy of the Swedish version.


Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
14 11 2022
Historique:
received: 14 07 2022
accepted: 04 11 2022
entrez: 15 11 2022
pubmed: 16 11 2022
medline: 18 11 2022
Statut: epublish

Résumé

The 14-item Short Health Anxiety Inventory (SHAI-14) is a common measure of health anxiety but its screening properties have not been studied. The aims of this study were to evaluate the SHAI-14 as a screening instrument, identify cut-offs for clinically significant health anxiety and investigate which scores correspond to different severity levels. The study included 1729 psychiatric patients and 85 healthy controls. Participants completed the SHAI-14 and underwent a diagnostic interview. Cut-off scores were evaluated in three scenarios to approximate screening 1) in a psychiatric clinic, 2) in a low prevalence setting and, 3) of healthy volunteers (cut-off for remission). Receiver operating characteristics were used. Classification of severity was based on the distribution of SHAI-14 scores reported by patients with clinically significant health anxiety. The area under the curve (AUC) values were high in all scenarios (above 0.95). The optimal cut-off scores on the SHAI-14 were 22 in the psychiatric context, 29 in a setting with low prevalence of psychiatric disorders and 18 versus healthy controls. SHAI-14 scores of 0-27 represented no or mild health anxiety, 28-32 moderate health anxiety and 33-42 substantial health anxiety. Brief self-report measures used as screening instruments are a simple way of gathering information about the presence of specific symptoms and thus a way to detect the likelihood of a diagnosis. The SHAI-14 shows evidence of good diagnostic utility in both clinical and non-clinical settings. However, which cut-off score is to be used, depends on the intended purpose and the setting where the cut-off is used.

Sections du résumé

BACKGROUND
The 14-item Short Health Anxiety Inventory (SHAI-14) is a common measure of health anxiety but its screening properties have not been studied. The aims of this study were to evaluate the SHAI-14 as a screening instrument, identify cut-offs for clinically significant health anxiety and investigate which scores correspond to different severity levels.
METHOD
The study included 1729 psychiatric patients and 85 healthy controls. Participants completed the SHAI-14 and underwent a diagnostic interview. Cut-off scores were evaluated in three scenarios to approximate screening 1) in a psychiatric clinic, 2) in a low prevalence setting and, 3) of healthy volunteers (cut-off for remission). Receiver operating characteristics were used. Classification of severity was based on the distribution of SHAI-14 scores reported by patients with clinically significant health anxiety.
RESULTS
The area under the curve (AUC) values were high in all scenarios (above 0.95). The optimal cut-off scores on the SHAI-14 were 22 in the psychiatric context, 29 in a setting with low prevalence of psychiatric disorders and 18 versus healthy controls. SHAI-14 scores of 0-27 represented no or mild health anxiety, 28-32 moderate health anxiety and 33-42 substantial health anxiety.
CONCLUSION
Brief self-report measures used as screening instruments are a simple way of gathering information about the presence of specific symptoms and thus a way to detect the likelihood of a diagnosis. The SHAI-14 shows evidence of good diagnostic utility in both clinical and non-clinical settings. However, which cut-off score is to be used, depends on the intended purpose and the setting where the cut-off is used.

Identifiants

pubmed: 36376898
doi: 10.1186/s12888-022-04367-3
pii: 10.1186/s12888-022-04367-3
pmc: PMC9664720
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

701

Informations de copyright

© 2022. The Author(s).

Références

Behav Ther. 2007 Mar;38(1):86-94
pubmed: 17292697
BMJ Open. 2016 Nov 3;6(11):e012914
pubmed: 27810977
J Anxiety Disord. 2010 Dec;24(8):931-5
pubmed: 20650601
Soc Psychiatry Psychiatr Epidemiol. 2014 Oct;49(10):1677-89
pubmed: 24632782
Br J Psychiatry. 2013 Jan;202(1):56-61
pubmed: 22500013
N Engl J Med. 1978 Oct 26;299(17):926-30
pubmed: 692598
J Anxiety Disord. 2015 Apr;31:32-7
pubmed: 25723780
Psychol Med. 2003 May;33(4):611-22
pubmed: 12785463
Depress Anxiety. 2012 Jul;29(7):652-64
pubmed: 22504935
BMC Med. 2019 Jan 23;17(1):16
pubmed: 30670044
J Psychosom Res. 2006 Feb;60(2):155-61
pubmed: 16439268
Compr Psychiatry. 2015 Nov;63:30-5
pubmed: 26555489
J Affect Disord. 2015 Mar 15;174:64-9
pubmed: 25486275
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
PLoS One. 2010 Mar 24;5(3):e9873
pubmed: 20352043
J Anxiety Disord. 2012 Jan;26(1):246-51
pubmed: 22169014
Stat Med. 2012 Oct 15;31(23):2676-86
pubmed: 22307964
Clin Psychol Psychother. 2009 Sep-Oct;16(5):431-43
pubmed: 19618479
Am J Psychiatry. 1993 Feb;150(2):197-206
pubmed: 8422070
Behav Res Ther. 2011 Nov;49(11):719-28
pubmed: 21839987
Expert Rev Pharmacoecon Outcomes Res. 2019 Dec;19(6):663-676
pubmed: 31859542
JAMA. 2004 Mar 24;291(12):1464-70
pubmed: 15039413
Depress Anxiety. 2002;15(4):183-5
pubmed: 12112724
J Psychosom Res. 2015 Apr;78(4):384-90
pubmed: 25592160
Stat Med. 1987 Jun;6(4):411-23
pubmed: 3114858
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
J Psychosom Res. 2017 Dec;103:9-14
pubmed: 29167052
J Neurosci Rural Pract. 2020 Jan;11(1):125-129
pubmed: 32140015
Med Care. 2001 Jul;39(7):705-15
pubmed: 11458135
Behav Res Ther. 2002 Jun;40(6):701-15
pubmed: 12051488
Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):353-64
pubmed: 23001456
J Clin Psychopharmacol. 1993 Oct;13(5):327-31
pubmed: 8227491
Cogn Behav Ther. 2016 Jun;45(4):259-69
pubmed: 27096407
Int J Epidemiol. 2014 Apr;43(2):476-93
pubmed: 24648481
BMC Psychiatry. 2007 Feb 06;7:7
pubmed: 17284321
Acta Psychiatr Scand. 1994 Jan;89(1):21-8
pubmed: 8140903
Anxiety Stress Coping. 2016;29(2):219-39
pubmed: 25846805
J Anxiety Disord. 2011 May;25(4):612-4
pubmed: 21354766
J Behav Med. 2009 Apr;32(2):150-61
pubmed: 19015971
Eur Psychiatry. 1998;13(1):26-34
pubmed: 19698595
Int J Soc Psychiatry. 2019 Nov;65(7-8):566-569
pubmed: 31379243
Psychol Med. 2009 Feb;39(2):277-85
pubmed: 18485260
BMC Med Res Methodol. 2003 Nov 10;3:25
pubmed: 14606960
J Gen Intern Med. 2006 Mar;21(3):267-75
pubmed: 16336622
J Anxiety Disord. 2013 Jan;27(1):68-78
pubmed: 23247202
J Psychosom Res. 2009 May;66(5):363-77
pubmed: 19379952
Psychol Med. 2002 Jul;32(5):843-53
pubmed: 12171378
J Psychosom Res. 2011 Dec;71(6):392-4
pubmed: 22118381

Auteurs

Susanna Österman (S)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77, Stockholm, Sweden. susanna.osterman@ki.se.

Erland Axelsson (E)

Division of psychology, Department of Clinical Neuroscience, Karolinska Institutet, Nobels väg 6, SE-17165, Stockholm, Sweden.
Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 23, SE-141 83, Huddinge, Sweden.
Liljeholmen Primary Health Care Clinic, Region Stockholm, Liljeholmstorget 7, SE-117 94, Stockholm, Sweden.

Nils Lindefors (N)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77, Stockholm, Sweden.

Erik Hedman-Lagerlöf (E)

Division of psychology, Department of Clinical Neuroscience, Karolinska Institutet, Nobels väg 6, SE-17165, Stockholm, Sweden.
Gustavsberg Primary Health Care Clinic, Region Stockholm, Odelbergs väg 19, SE-134 40, Gustavsberg, Sweden.

Maria Hedman-Lagerlöf (M)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, SE-113 64, Stockholm, Sweden.

Dorian Kern (D)

Division of psychology, Department of Clinical Neuroscience, Karolinska Institutet, Nobels väg 6, SE-17165, Stockholm, Sweden.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, SE-113 64, Stockholm, Sweden.

Cecilia Svanborg (C)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77, Stockholm, Sweden.

Volen Z Ivanov (VZ)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, SE-171 77, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH